Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorXinqiao Hospital of Chongqing
About this trial
1. To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and provides a basis for subsequent large-scale research and clinical application. 2. To evaluate the changes of cytokines and verify the effect of some cytokines on the efficacy of cetuximab +FOLFIRI, so as to provide a scientific basis for the subsequent precise therapy using cytokines antibodies.
Eligibility criteria
Qualifiers
Patients with RAS and BRAF wild-type IV unresectable left colorectal cancer confirmed by pathology and tissue/cytology and genetic testing;
Physical state is good: PS 0-2;
Expected survival of more than 3 months;
Aged 18-75 years old;
Disqualifiers
Patients with severe dysfunction of vital organs (heart, liver, kidney);
Patients with other malignant tumors;
Patients who are pregnant or breastfeeding (women of childbearing age need to check pregnancy test);
In the active phase of acute or chronic infectious diseases;
Trial design
Treatments tested in this trial
- Thalidomide+cetuximab+FOLFOX/FOLFIRI
Treatment groups
96 Participants
are divided into 2 treatment groupsSponsors and collaborators
Xinqiao Hospital of Chongqing
Lead sponsor
Chongqing Medical University
Collaborator
Source ClinicalTrials.gov